Bantam Pharmaceutical
First in class small molecule cancer therapeutics for hematological malignancies and select solid tumors
First in class small molecule cancer therapeutics for hematological malignancies and select solid tumors
Bantam Pharmaceutical is a pioneering drug discovery company focused on developing first-in-class small molecule cancer therapeutics for hematological malignancies and select solid tumors. Leveraging their expertise in mitochondrial dynamics, the company is dedicated to addressing unmet needs in oncology. Their lead candidate, BTM-3566, is an orally-available novel small molecule compound targeting Diffuse Large B-cell Lymphomas (DLBCL) and other hematologic and solid tumors. What sets BTM-3566 apart is its unique mechanism of action, disrupting mitochondrial function in tumor cells to induce apoptosis. Currently pursuing an IND application for B-cell malignancies, Bantam Pharmaceutical's vision, and potential impact is attracting attention in the Health Care and Pharmaceutical industries. In September 2021, the company secured a significant $25.00M Seed Round investment led by Lionel Goldfrank, indicating growing confidence in their innovative approach. With a founding year of 2015, Bantam Pharmaceutical's progress is positioning them as a promising player in the biotech landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $25.00M | 1 | Lionel Goldfrank | 16 Sep 2021 |
No recent news or press coverage available for Bantam Pharmaceutical.
We care about your data, and we'd love to use cookies make your experience better.